You Searched For: 3-Amino-4-butoxybenzoic acid

Upstream Gene Therapy Products & Solutions in Bioprocessing Achieve optimal generation of gene therapy vectors with our non-viral transfection and viral transduction products. Avantor® can provide culture systems that support processes development...

Upstream processing for vaccines Optimal production of vaccines is achieved in mammalian expression and insect systems using cell lines that are anchorage-dependent or suspension enabled. For most vaccines, optimal production is achieved in mammal...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Aurora Manufacturing Facility Our 65000 sq. ft. manufacturing facility in Aurora OH USA includes a 12000 sq. ft. excipient processing center 3000 sq. ft. for repackaging 35000 sq. ft. warehouse 8000 sq. ft. office 8000 sq. ft. manufacturing area a...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...

Aurora Manufacturing Facility Our 65000 sq. ft. manufacturing facility in Aurora OH USA includes a 12000 sq. ft. excipient processing center 3000 sq. ft. for repackaging 35000 sq. ft. warehouse 8000 sq. ft. office 8000 sq. ft. manufacturing area a...

Aurora Manufacturing Facility Our 65000 sq. ft. manufacturing facility in Aurora OH USA includes a 12000 sq. ft. excipient processing center 3000 sq. ft. for repackaging 35000 sq. ft. warehouse 8000 sq. ft. office 8000 sq. ft. manufacturing area a...

Aurora Manufacturing Facility Our 65000 sq. ft. manufacturing facility in Aurora OH USA includes a 12000 sq. ft. excipient processing center 3000 sq. ft. for repackaging 35000 sq. ft. warehouse 8000 sq. ft. office 8000 sq. ft. manufacturing area a...